^
Association details:
| Biomarker: | CCDC86 expression + NPM1 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
Published date:
11/24/2021
Excerpt:
To evaluate the clinical implication of NPM1 in DLBCL, NPM1 immunohistochemistry (IHC) was carried out on a representative cohort of 97 R-CHOP-treated DLBCL patients in which CYCLON expression was previously investigated [11] using tissue microarray (TMA)....Kaplan Meier survival analyses revealed that CYCLON/NPM1 double expressors DLBCL were significantly associated with an inferior outcome in terms of progression-free survival (PFS, Figure 2B, p = 0.021) compared to DLBCL expressing only CYCLON.
DOI:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656558/
